Compass Therapeutics Inc.

Compass Therapeutics expects feedback from the FDA this quarter on Phase 2/3 data for tovecimig in biliary tract cancer, prior to a potential BLA filing later this year. The overall response rate in the final analysis improved to 18.0% from a previously reported 17.1%, with a p-value of 0.0228 compared to paclitaxel alone. The company also reported that CTX-8371 Phase 1 cohort expansions are enrolling patients with triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer, while the first patients have been dosed in the Phase 1 study of CTX-10726. Compass ended the second quarter of 2026 with $180 million in cash and marketable securities, which is expected to fund operations into 2028.

Compass Therapeutics announced that its abstract on tovecimig has been accepted for an oral Proffered Paper presentation at the European Society for Medical Oncology Congress 2026. The presentation will highlight results from the randomized, controlled Phase 2/3 COMPANION-002 clinical trial evaluating tovecimig, a DLL4 x VEGF-A bispecific antibody, in combination with paclitaxel in patients with advanced biliary tract cancer. The trial data will be presented by Dr. Nilofer Azad of Johns Hopkins University on Saturday, October 24, 2026, during a session from 10:15am to 11:45am CET. The ESMO Congress will take place October 23-27, 2026 in Madrid, Spain.

Compass Therapeutics plans to meet with the FDA ahead of a potential approval application for its experimental cancer drug tovecimig in biliary tract cancer later in 2026. The company announced in its May 5 first-quarter update that tovecimig received FDA Orphan Drug Designation in April, a status for treatments targeting rare diseases. A late-stage study showed stronger tumor response and longer disease control than chemotherapy alone. Compass also began a Phase 1 study for another experimental cancer treatment, CTX-10726, with initial data expected in the fourth quarter of 2026. The company ended the first quarter with $195 million in cash and marketable securities, which it expects to fund operations into 2028.